RxDoctor Payments Data

Ricardo Caldera, MD

Internal Medicine · Washington, DCNPI 1053420646

Payments from drug & device makers

$881in general payments, 2019–2025

Across 41 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$253
  • Boehringer Ingelheim$112
  • Bayer$86
  • Viiv Healthcare Company$80
  • GSK$62
  • Johnson & Johnson$51
  • plus $237 from 9 others

What the payments were for

  • Food & beverage$881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$881 in reported general payments places this provider in the 75th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$55,743
Medicare patients
172
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala68$275,046
TriumeqAbacavir/Dolutegravir/Lamivudi64$246,652
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$89,151
DovatoDolutegravir Sodium/Lamivudine16$53,095
OzempicSemaglutide32$44,068
TivicayDolutegravir Sodium16$37,865
DescovyEmtricitabine/Tenofov Alafenam14$31,854
EliquisApixaban16$24,481
JanuviaSitagliptin Phosphate25$23,421
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$23,067
JardianceEmpagliflozin23$16,124
JanumetSitagliptin Phos/Metformin Hcl13$10,005
TradjentaLinagliptin11$7,800
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,384
Serevent DiskusSalmeterol Xinafoate14$5,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$253$396,051103 claims
Viiv Healthcare CompanyTriumeq, Dovato, Tivicay$80$337,61296 claims
Novo NordiskOzempic$21$44,06832 claims
MerckJanuvia, Janumet$33$33,42738 claims
PfizerEliquis$38$24,48116 claims
Boehringer IngelheimJardiance, Tradjenta$112$23,92434 claims
GSKArnuity Ellipta$62$2,41111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →